| 名稱 | MG-132 |
| 描述 | MG-132 (Z-Leu-Leu-Leu-al) is a 26S proteasome inhibitor (IC50=100 nM) that is cell-permeable and reversible. MG-132 acts as an autophagy activator and also induces apoptosis. |
| 細(xì)胞實(shí)驗(yàn) | The effect of MG132 on HeLa cell growth was determined by trypan blue exclusion cell counting or measuring MTT dye absorbance of living cells as previously described. In brief, cells (5x10^5 cells per well) were seeded in 24-well plates for cell counting, and cells (5x10^4 cells per well) were seeded in 96-well microtiter plates for the MTT assay. After exposure to indicated amounts of MG132 for 24 h, cells in 24-well plates or 96-well plates were collected with trypsin digestion for trypan blue exclusion cell counting or were used for the MTT assay. Twenty microliters of MTT solution (2 mg/ml in PBS) was added to each well of 96-well plates. The plates were again incubated for 4 h at 37?C. MTT solution in the medium was aspirated off and 200 μl of DMSO was added to each well to solubilize the formazan crystals formed in viable cells. Optical density was measured at 570 nm using a microplate reader. Each plate contained multiple wells at a given experimental condition and multiple control wells. This procedure was replicated for 2-4 plates per condition [3]. |
| 激酶實(shí)驗(yàn) | Inhibitory activities of ZLLa1 and ZLLLal against m-calpain and 20S proteasome were measured by previously described methods.For the m-calpain inhibitory assay,the 0.5 ml reaction mixture contained 0.24% alkali-denatured casein,28 mM 2-mercaptoethanol,0.94 unit of m-calpain,ZLLal or ZLLLal,6 mM CaCl2,and 0.1M Tris-HC1 (pH 7.5).The reaction was started by the addition of m-calpain solution and stopped by the addition of 0.5 ml of 10% trichloroacetic acid after incubation at 30℃ for 15 min.After centrifugation at 1,300×g for 10 min,the absorbance of the supernatant at 280 nm was measured.The reaction mixture for the 20S proteasome inhibitory assay contained 0.1 M Tris-acetate,pH 7.0,20S proteasome,ZLLa1 or ZLLLal,and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 ml.After incubation at 37℃ for 15 min,the reaction was stopped by the addition of 0.1 ml of 10% SDS and 0.9 ml of 0.1 M Tris-acetate,pH 9.0.The fluorescence of the reaction products was measured.To determine the IC50s against m-calpain and 20S proteasome,various concentrations of the synthetic peptide aldehydes were included in the assay mixture [1]. |
| 動物實(shí)驗(yàn) | Male Sprague–Dawley rats (8 weeks old, 180 – 230 g) were used to establish a pressure-overload model as described previously. All animals were separated into four groups (10 rats per group): (i) vehicle-treated sham group; (ii) MG132-treated sham group; (iii) vehicle-treated abdominal aortic banding (AAB) group; and (iv) MG132-treated AAB group. Under intraperitoneal pentobarbital (50 mg/kg) anesthesia, AAB was created using a 5-0 suture tied twice around the abdominal aorta in which. a 21-gauge needle was inserted. The needle was then retracted yielding a 70 – 80% constriction with an outer aortic diameter of 0.8 mm. In the sham surgery rats, the same surgery was performed as described above except the aorta was constricted. At Day 3 after the surgery, MG132-treated rats were intraperitoneally injected with 0.1 mg/kg/day of MG132 for 8 weeks. All control animals were injected with a corresponding volume of vehicle only (0.1% DMSO) [4]. Sixteen-week-old male CD1 mice were used for all our experiments. Thirty minutes before the immobilization procedure, 0.1 mg/kg of buprenorphine was administrated IP. The mice were then anesthetized using isoflurane. The right hindlimb was immobilized as previously described. Briefly, the hindlimb was immobilized 7 days by stapling the foot exploiting normal dorso-tibial flexion using an Autosuture Royal 35W skin stapler. One tine was inserted close to the toe at the plantar portion of the foot while the other was inserted in the distal portion of the gastrocnemius. The other hindlimb was used as a control. During the immobilization period, the mice were injected subcutaneously with MG132 (7.5 mg/kg/dose) or vehicle (DMSO) twice daily. DMSO containing or not MG132 was diluted in sterile pure corn oil (1:100, injected volume 150 μL). After 7 days, the tibialis anterior (TA) muscles of immobilized and non-i |
| 體外活性 | 方法：人宮頸癌細(xì)胞 HeLa 用 MG-132 (0.5-30 μM) 處理 24 h，使用 MTT 方法檢測細(xì)胞生長抑制情況。
結(jié)果：MG-132 劑量依賴性地抑制 HeLa 細(xì)胞生長，IC50 約為 5 μM。[1]
方法：人間皮瘤細(xì)胞 NCI-H2452 用 MG-132 (0.25-2 μM) 處理 36 h，使用 Western Blot 方法檢測靶點(diǎn)蛋白表達(dá)水平。
結(jié)果：MG-132 處理誘導(dǎo) NCI-H2052 細(xì)胞中 caspases 3、caspases 7、Bid 和 PARP 的切割，誘導(dǎo) caspase 依賴性凋亡。[2]
方法：人類黑色素瘤細(xì)胞 MeWo 用 MG-132 (0.01-1 μM) 處理 24 h，使用 Flow Cytometry 方法分析細(xì)胞周期情況。
結(jié)果：MG-132 誘導(dǎo) MeWo 細(xì)胞的細(xì)胞周期阻滯在 G2 期。[3] |
| 體內(nèi)活性 | 方法：為檢測體內(nèi)抗腫瘤活性，將 MG-132 (1 mg/kg) 靜脈注射給攜帶人宮頸癌腫瘤 HeLa、CaSki 或 C33A 的 C.B‐17/lcr‐scid/scidJcl 小鼠，每周兩次，持續(xù)四周。
結(jié)果：MG-132 治療顯著抑制人宮頸癌腫瘤的生長，表明在體內(nèi)具有抗腫瘤活性。[4]
方法：為研究 MG-132 長期治療對心肌肥大的影響及其相關(guān)分子機(jī)制，將 MG-132 (0.1 mg/kg) 腹腔注射給具有腹主動脈束帶（AAB）的大鼠，每天一次，持續(xù)八周。
結(jié)果：MG-132 治療顯著減弱了 AAB 大鼠的左心室肌細(xì)胞面積、左心室重量/體重和肺重量/體重比，降低了左心室舒張直徑和壁厚，并增加了縮短分?jǐn)?shù)。MG-132 治療可顯著逆轉(zhuǎn) AAB 大鼠 ERK1/2 和 JNK1 磷酸化水平的升高。[5] |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | H2O : Insoluble
Ethanol : 47.5 mg/mL (100 mM)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 9 mg/mL (18.92 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
DMSO : 45 mg/mL (94.61 mM)
|
| 關(guān)鍵字 | proteolytic | Proteasome | peptide | MG-132 | MG132 | MG 132 | Inhibitor | inhibit | complex | calpain | Autophagy | Apoptosis | aldehyde | 26S |
| 相關(guān)產(chǎn)品 | Guanidine hydrochloride | Naringin | Valproic Acid | L-Glutamic acid | Gefitinib | Hydroxychloroquine | Dextran sulfate sodium salt (MW 4500-5500) | Stavudine | Tributyrin | L-Ascorbic acid | Paeonol | Sodium 4-phenylbutyrate |
| 相關(guān)庫 | 抑制劑庫 | 抗癌活性化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 細(xì)胞凋亡化合物庫 | 抗衰老化合物庫 | 蛋白酶抑制劑庫 | 抗COVID-19化合物庫 | NO PAINS 化合物庫 | 泛素化化合物庫 | 血液病分子庫 | 共價(jià)抑制劑庫 |